VBLT News and Press, Vascular Biogenics Ltd. From 09/15/20

TEL AVIV, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) will present today a corporate overview, including an update on the OVAL pivotal study, at the H. C. Wainwright 22nd Annual Global Investment Conference being held virtually on September 14-16, 2020. ...

Mallinckrodt (NYSE: MNK )   -14%  on FDA rejection of terlipressin for type of kidney failure. More news on: Mallinckrodt plc, Taoping Inc., Nikola Corporation, Stocks on the move, , Read more ...

VBL Therapeutics (NASDAQ: VBLT )   jumps 14%  premarket on heels of new data demonstrating ex-vivo activity of its investigational anti-MOSPD2 (motile sperm domain-containing protein 2) mAbs in patients with relapsing-remitting and progressive multiple sclerosis (MS). Th...

Vascular Biogenics (NASDAQ: VBLT ) +32%  on strong preclinical results of MOSPD2 program. More news on: Vascular Biogenics Ltd., Genetic Technologies Limited, Eastman Kodak Company, Stocks on the move, , Read more ...

TEL AVIV, Israel, Sept. 11, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investigational anti-MOSPD2 mAbs in patients with relapsing-remitting and progressive multiple sclerosis...

The first two participants have been enrolled in a Phase 2 clinical trial evaluating the combination of VBL Therapeutics' ( VBLT +0.9% ) VB-111 and Bristol Myers Squibb's ( BMY -0.1% ) Opdivo (nivolumab) in metastatic colorectal cancer patients. More news on: Vascular Biogenics Ltd...

Study to investigate for the first time a combination of VB-111 with the checkpoint inhibitor, nivolumab. TEL AVIV, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the first two patients have been enrolled in the Phase 2 clinical trial...

Alignment with FDA on the path forward for the development of VB-601 TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today the successful completion of a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding...

VBL Therapeutics reports progress for ovarian cancer drug candidate VBL Therapeutics ( VBLT ) announced the progress for its Phase 3 OVAL trial for platinum resistant ovarian cancer. The overall survival data from the trial was unblinded and reviewed by the independent Data Safety Monito...

Vascular Biogenics Ltd (VBLT) Q2 2020 Earnings Conference Call August 13, 2020, 08:30 ET Company Participants Michael Wood - LifeSci Advisors Dror Harats - CEO & Director Amos Ron - CFO & Company Secretary Conference Call Participants Kevin DeGeeter - Oppenheimer ...